Schulte Roth & Zabel represented Deep Track Capital, while Crandon Law represented TORL BioTherapeutics in the transaction.TORL BioTherapeutics announced its closing of an oversubscribed $158 million Series B-2…
TORL BioTherapeutics’ $158 Million Series B-2 Financing
![](https://globallegalchronicle.com/wp-content/uploads/2024/05/torl-biotherapeutics-158-million-series-b-2-financing_6639de0022592-480x360.jpeg)